Evidence map›Paper›PMID 31382623›Full record

ArticleCells2019

Investigation of Cytokine Changes in Osteoarthritic Knee Joint Tissues in Response to Hyperacute Serum Treatment.

Dorottya Kardos, Bence Marschall, Melinda Simon, István Hornyák, Adél Hinsenkamp, Olga Kuten, Zsuzsanna Gyevnár, Gábor Erdélyi, Tamás Bárdos, Tamás Mirkó Paukovits and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04345679 (Anti COVID-19 Convalescent Plasma Therapy), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04345679 early_phase1unknown statusnot on this mapstarted 2020, after this paper: background citation

Anti COVID-19 Convalescent Plasma Therapy

TypeinterventionalSponsorOrthosera Kft.Ran2020 to 2021Enrolled20ConditionsCOVID 19Armsanti-SARS-CoV-2 convalescent plasma
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Albumin as a Biomaterial and Therapeutic Agent in Regenerative Medicine.International journal of molecular sciences · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Dorottya KardosInstitute Clinical Experimental Research, Semmelweis University, Budapest 1094, Hungary. dorottya333@gmail.com.ORCID 0000-0001-7886-0244
Bence MarschallInstitute Clinical Experimental Research, Semmelweis University, Budapest 1094, Hungary.ORCID 0000-0001-9411-9528
Melinda SimonInstitute Clinical Experimental Research, Semmelweis University, Budapest 1094, Hungary.
István HornyákInstitute Clinical Experimental Research, Semmelweis University, Budapest 1094, Hungary.
Adél HinsenkampInstitute Clinical Experimental Research, Semmelweis University, Budapest 1094, Hungary.
Olga KutenCenter for Regenerative Medicine, Danube University, Krems-an-der-Donau 3500, Austria.ORCID 0000-0002-1827-1314
Zsuzsanna GyevnárInstitute Sport and Health Sciences, University of Physical Education, Budapest 1123, Hungary.
Gábor ErdélyiKastelypark Clinic, Tata 2980, Hungary.
Tamás BárdosKastelypark Clinic, Tata 2980, Hungary.
Tamás Mirkó PaukovitsKastelypark Clinic, Tata 2980, Hungary.
Krisztián MagosKastelypark Clinic, Tata 2980, Hungary.
György BéresKastelypark Clinic, Tata 2980, Hungary.
Kálmán SzentheRT-Europe Nonprofit Research Center, Mosonmagyaróvár 9200, Hungary.
Ferenc BánátiRT-Europe Nonprofit Research Center, Mosonmagyaróvár 9200, Hungary.
Susan SzathmaryGalenbio Ltd., Mosonmagyaróvár 9200, Hungary.
Stefan NehrerCenter for Regenerative Medicine, Danube University, Krems-an-der-Donau 3500, Austria.
Zsombor LaczaInstitute Clinical Experimental Research, Semmelweis University, Budapest 1094, Hungary.
Semmelweis University · HUUniversität für Weiterbildung Krems · ATHungarian University of Sports Science · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One option to fight joint degradation and inflammation in osteoarthritis is the injection of activated blood products into the synovial space. It has been demonstrated that hyperacute serum is the most proliferative among plasma products, so we investigated how the cytokine milieu of osteoarthritic knee joint reacts to hyperacute serum treatment in vitro. Cartilage, subchondral bone, and synovial membrane explanted from osteoarthritic knees were stimulated by interleukin-1 beta (IL-1β) and the concentration of 39 biomarkers was measured in the co-culture supernatant after hyperacute serum treatment. The IL-1β stimulation triggered a strong inflammatory response and enhanced the concentrations of matrix metalloproteinase 3 and 13 (MMP-3 and MMP-13), while hyperacute serum treatment reduced inflammation by decreasing the concentrations of IL-1β, tumor necrosis factor alpha (TNF-α), interleukin-6 receptor alpha (IL-6Rα), and by increasing the level of interleukin-1 antagonist (IL-1RA) Cell viability increased by day 5 in the presence of hyperacute serum. The level of MMPs-1, 2, and 9 were higher on day 3, but did not increase further until day 5. The concentrations of collagen 1 alpha 1 (COL1A1) and osteonectin were increased and receptor activator of nuclear factor kappa-B ligand (RANKL) was reduced in response to hyperacute serum. We concluded that hyperacute serum treatment induces cell proliferation of osteoarthritic joint tissues and affects the cytokine milieu towards a less inflamed state.

Indexed as

AdultCartilageCoculture TechniquesCytokinesFemaleHumansInterleukin-1betaKnee JointMaleMiddle AgedOsteoarthritis, KneeSynovial MembraneTissue Culture TechniquesYoung AdultCytokinesIL1B protein, humanInterleukin-1betabone remodelinghyperacute seruminflammatory cytokinesknee osteoarthritismatrix metalloproteases

Identifiers

PMID31382623
PMCPMC6721638
OpenAlexW2965918230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.